Company intelligence
Northstar Oncology by BillionToOne
About Northstar Oncology by BillionToOne
Northstar Oncology delivers precision liquid biopsy tests to improve cancer care. Our platform is built to detect actionable signals others may miss, empowering providers to navigate therapy selection and monitor response with clarity and confidence. → Northstar Select® is the most sensitive ctDNA-based therapy selection profile, uncovering over 50% more clinically actionable information and reducing false negative null reports by half. → Northstar Response® is the only tissue-free methylation-based treatment monitoring test with single-molecule precision that offers real-time insights into molecular progression. Northstar delivers the clarity providers need to plan treatment confidently—giving patients a clearer path forward. See how Northstar can help optimize treatment planning for advanced cancers → www.northstaronc.com
Verified activity
Signals from Northstar Oncology by BillionToOne
5 published signals
Products & Services
Northstar Oncology by BillionToOne released its newest test, Northstar Origin, which runs on the same Northstar Select sample and delivers results in 5–8 days.
Reported by Northstar Oncology by BillionToOne
Products & Services
Northstar Oncology by BillionToOne expanded its comprehensive genomic profiling panel by adding MTAP deletion and a copy number loss biomarker that's typically hard for liquid biopsy to detect.
Reported by Northstar Oncology by BillionToOne
Presence & Recognition
Northstar Oncology by BillionToOne is hosting a webinar titled Solving the Unknown: Tissue of Origin, CUP, and the Role of Northstar Origin™ on September 22 at 12:00 PM PST/3:00 PM EST.
Reported by Northstar Oncology by BillionToOne
Research & Knowledge
Northstar Oncology by BillionToOne announced that Northstar Origin is now available for use in LiquidBiopsy.
Reported by Cinderella Koga, MBA, CT(ASCP)
Products & Services
Northstar Oncology by BillionToOne launched Northstar Origin, an add-on to Northstar Select designed to predict tissue of origin directly from circulating tumor DNA (ctDNA) in 91% of cases.
Reported by Northstar Oncology by BillionToOne